Multiple Sclerosis with Uncommon Cerebrospinal Fluid Findings

Croatian Medical Journal

Volumn 44, Issue 6, 2003, Pages 697-701

  Rot, Uroš ^a   Mesec, Anton ^a   Pogačnik, Tomaž ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Cerebrospinal fluid; Immunoglobulins; Leukocytes, mononuclear; Multiple sclerosis

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; BORRELIA INFECTION; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC TEST; FEMALE; HUMAN; IMMUNOMODULATION; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEOCYTOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; RETROSPECTIVE STUDY;

ADULT; AGED; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; RETROSPECTIVE STUDIES;

EID: 0345828874     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Walker RW, Thompson EJ, McDonald WI. Cerebro-spinal fluid in multiple sclerosis: relationships between immunoglobulins, leukocytes and clinical features. J Neurol 1985;232:250-9.
2. Zeman AZ, Kidd D, McLean BN, Kelly MA, Francis DA, Miller DH, et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:27-30.
3. McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 1990;113(Pt 5):1269-89.
4. Rudick RA, Schiffer RB, Schwetz KM, Herndon RM. Multiple sclerosis. The problem of incorrect diagnosis. Arch Neurol 1986;43:578-83.
5. Stendahl-Brodin L, Link H. Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1980;43:102-5.
6. Francis GS, Duquette P, Antel JP. Inflammatory demyelinating diseases of the nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in clinical practice. Boston (MA): Butter-worth-Heinemann; 1996. p. 1307-43.
7. Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.
8. Bharuca NE. Infections of the nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in clinical practice. Boston (MA): Butterworth-Heinemann; 1996. p. 1181-306.
9. Jennekens FG, Kater L. Neurology of the inflammatory connective tissue diseases. London: Saunders Co.; 1999.
10. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000;79:57-68.
11. Kinnunen E, Muller K, Keto P, Ketonen L, Helve T, Sepponen R. Cerebrospinal fluid and MRI findings in three patients with multiple sclerosis and systemic lupus erythematosus. Acta Neurol Scand 1993;87:356-60.
12. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
13. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
14. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brown-scheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
15. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001;357:1576-82.
16. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
17. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-5.
18. Reiber H. A rapid and simple nephelometric assay for total protein in cerebrospinal fluid (author's transl) [in German]. J Clin Chem Clin Biochem 1980;18:123-7.
19. Siden A, Kjellin KG. CSF protein examinations with thin-layer isoelectric focusing in multiple sclerosis. J Neurol Sci 1978;39:131-46.
20. Farrell MA, Kaufmann JC, Gilbert JJ, Noseworthy JH, Armstrong HA, Ebers GC. Oligoclonal bands in multiple sclerosis: clinical-pathologic correlation. Neurology 1985;35:212-8.
21. Pirttila T, Nurmikko T. CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis. Acta Neurol Scand 1995;92:468-71.
22. Link H, Mueller R. Immunoglobulins in multiple sclerosis and infections of the nervous system. Arch Neurol 1971;25:326-44.
23. Olsson JE, Link H. Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol 1973;28:392-9.
24. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38:1822-5.
25. Gallo P, Tavolato B, Bergenbrant S, Siden A. Immunoglobulin light chain patterns in the cerebrospinal fluid. A study with special reference to the occurence of free light chains in cerebrospinal fluid with and without oligoclonal immunoglobulin G. J Neurol Sci 1989;94:241-53.